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Introduction
Tailored therapy has become a term popularly used (and
misused) with respect to cancer therapy. Everybody spots
the difference between having a full tailormade suit or dress
versus simply cutting the last 5 cm off the legs of some
readymade trousers to fit your length. In parallel, tailormade
therapy should not be confused with implementing simple
prognostic or predictive factors. These parameters, in general,
do not define direct biological targets, but rather biological
parameters revealing a variable statistical correlation to
outcome [1]. Taking the analogy of clothes manufacturing,
the definition of tailored therapy (made for you) should imple-
ment targeted therapies based on identification of individual
therapeutic targets such as HER2 in the tumour tissue [2],
providing a target exclusive to this tumour for therapeutic
attack [3].
In theory, a similar discussion should be applied not only to
“targeted” therapy but to anticancer strategies in general,
including options like cytotoxic therapy as well. On the one
hand, parameters such as the histological grade as well as
gene expression profiles revealed by microarrays provide
moderate statistical correlates to outcome [4] but do not
define biological targets. In contrast, a parameter such as
topoisomerase II may be considered borderline in this
respect. The fact that this enzyme is a direct target of
anthracyclines, and amplification of its gene has been related
to improved sensitivity to anthracycline therapy [5,6],
suggests anthracycline-based chemotherapy to be a
tailormade therapy for topoisomerase-II-amplified tumours.
On the other hand, topoisomerase II overexpression is not
mandatory for anthracycline response, and evidence regard-
ing its predictive role remains conflicting [7].
In the present article we will briefly go through the potential for
tailormade treatment in breast cancer. As may be seen, most
breast cancer patients already receive some form of tailored
therapy, and recent evidence suggests novel highly innovative
tailored approaches to be on their way into the clinic.
Breast cancer taxonomy
It is conventional wisdom that breast cancers may be separ-
ated into two categories – so-called oestrogen receptor (ER)-
positive tumours versus ER-negative tumours. What remains
more controversial is the exact definition of receptor positivity;
should we consider 1% or 10% of cells expressing positive
staining as the lower limit, and should staining intensity be
taken into account [8]?
Breast cancers have more recently been separated into five
distinct classes based on gene expression profiles (Figure 1):
the luminal A and luminal B classes, the HER2 and basal
classes, and, finally, so-called normal breast-like tumours [9].
The different tumour categories express distinct gene expres-
sion profiles; in addition, the different classes reveal different
prognoses [9,10]. While the different classes do not predict
responsiveness to anthracycline-based or mitomycin-based
chemotherapy [11], tumours belonging to the different classes
may be subject to different targeted, or tailored, therapeutic
approaches. The following discussion on targeted therapy
will therefore be based on this classification.
Luminal A and luminal B tumours
While revealing certain differences regarding gene expres-
sion profiles, the luminal A and luminal B classes together
harbour tumours expressing the ER. It is now well established
that antihormonal therapy (either with use of anti-oestrogens
or through oestrogen suppression) works by depriving
tumour cells of ligand ER activation; therefore the fact that
endocrine therapy may work only among tumours expressing
the ER [12] reveals endocrine therapy based on ER
assessment actually to be the first as well as the most used
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tailored therapy in oncology. The fact that many ER-positive
tumours do not benefit from endocrine therapy [13]
resembles what is observed with respect to other targeted
therapies as well [3], and may be due to potential distur-
bances in other genes involved in complex downstream
pathways [14-16].
In conclusion, endocrine therapy fulfils the definition of a
tailormade therapy: depriving ER-positive breast cancer cells
of their oestrogen ligand stimulation has dramatic effects on
cell growth [17], and contemporary adjuvant therapy for ER-
positive breast cancer reduces the relapse rate by >30%
[12]. In general, tumours belonging to the luminal A class
express the ER to a higher level as compared with tumours
belonging to the luminal B class, and indirect evidence
suggests tamoxifen to be more effective among luminal A
tumours as compared with luminal B tumours [10].
Interestingly, recent evidence has suggested HER2 may play
a role to endocrine resistance in some ER-positive tumours
not amplified for the HER2 gene (see below). The fragile side
of tailored endocrine therapy, like all other anticancer
therapeutics, lies in the fact that we (in contrast to the tailor)
do not understand all measures to be taken to create the
perfect fit; we do not understand the mechanism of therapy
resistance. This lack of knowledge is illustrated by the fact that
the majority of ER-positive breast cancers are not cured in the
adjuvant setting, as well as the fact that endocrine treatment of
metastatic disease (like all other therapeutic manoeuvres in this
setting) remains palliative.
HER2 class tumours
These tumours in general are characterized by over-
expression of a variable number of genes located on the
same amplicon as HER2. Tailored therapy for these patients
should be separated into two topics: the role of HER2
targeting, and the potential predictive role of the HER2 class
(or amplification of certain genes within this class) as
predictive factors for chemotherapy sensitivity.
Proof of concept for the therapeutic benefit of targeting
HER2 with trastuzumab was revealed in metastatic disease
[18]. While response rates were modest and of limited
duration, implementation of trastuzumab in concert with
chemotherapy provided dramatic benefits in the adjuvant
setting [3,19]. Notably, effective anti-HER2 therapy is not
limited to trastuzumab; such effects may be achieved with
different tyrosine kinase inhibitors preventing HER2 activation
[20,21]. Interestingly, recent evidence now suggests that
lapatinib and trastuzumab administered in concert may
improve outcome as compared with lapatinib monotherapy in
cases of trastuzumab failure [22]; there is also evidence that
lapatinib may improve efficacy of aromatase inhibition for
patients harbouring ER-positive tumours nonamplified for
HER2 failing tamoxifen treatment [23]. Interestingly, treatment
with aromatase inhibitors has been shown to upregulate
HER2 expression in HER2 nonamplified tumours [24]. While
the mechanisms of resistance to endocrine therapy remains
complex [25], these data suggest a possibility to circumvent
this resistance, at least in some patients. The biological
characterization of these mechanisms and the potential for
upfront identification of patients benefiting from combined
treatment, however, remain to be elucidated.
A second issue relates to chemotherapy regimen selection.
There are several studies revealing a dose–response benefit
for anthracyclines in HER2-overexpressing tumours not
detected among tumours expressing HER2 at normal levels
[26-28]. This effect has been related to co-amplification of
topoisomerase II [5,6,29], located on the HER2 amplicon.
These results, however, have not been consistently repro-
duced [7]. HER2 and topoisomerase II are located on
chromosome 17, which in addition harbours several other
genes involved in processes like DNA repair and apoptosis.
Trisomy of this chromosome occurs in many breast cancers,
and some studies have actually suggested chromosome 17
trisomy to be a better predictor of anthracycline sensitivity as
compared with HER2 or topoisomerase II amplification [30,31].
Figure 1
Classes of breast cancer based on gene expression profiles. Gene
expression pattern of 85 experiment samples representing 78
carcinomas, three benign tumours and four normal tissues. Basal,
basal-like cell class; HER2, HER2 class; Nor, normal cell-like class;
LUM B A, luminal B and luminal A classes, respectively. Note: in the
initial work light blue was termed luminal C class while yellow was
luminal B – these two classes together now are grouped as luminal B.
Adapted from [9].In conclusion, tailored therapy targeting HER2 is an estab-
lished treatment option in breast cancer, and recent evidence
suggests an extended role for such strategies in the future.
While much evidence suggests a correlation between HER2
amplification and sensitivity to anthracylines, we lack a
complete understanding of the mechanisms involved.
Basal-like tumours
The basal-like tumours are characterized by a particular gene
expression profile, in general lacking expression of the ER as
well as the progesterone receptor and HER2. While the term
triple-negative breast cancer has come into common use, it
should not be used synonymously with the term basal-like
breast cancer. Tumours of the basal-like class may account
for about 60 to 80% of all triple-negative tumours only
[32,33], the residual in general belonging to the so-called
normal breast-like class.
Gene expression profiles suggest most tumours arising in
BRCA1 mutation carriers to belong to the basal class [10].
While probably around 10% of all basal-like tumours arise in
BRCA1 mutation carriers [34], there is evidence suggesting
that many more basal-like tumours may harbour disturbances in
the BRCA1 pathway [35]. In contrast, no distinct gene expres-
sion profile for BRCA2 mutated tumours has been identified.
BRCA1 as well as BRCA2 mutated tumours harbour defects in
homologous repair, one of the key DNA repair pathways in
response to double-strand DNA breaks [36]. This leads to
development of poly(ADP-ribose) polymerase (PARP) inhibitors
preventing DNA repair through alternative pathways [37].
These drugs should therefore work selectively against tumour
cells harbouring these defects. Indeed, use of PARP inhibitors
as monotherapy has revealed objective responses in metastatic
breast carcinomas [38] as well as in ovarian carcinomas [39].
In addition, when metastatic breast cancer patients were
treated with a gemcitabine/carboplatin regimen with or without
a PARP inhibitor [40], addition of the inhibitor improved the
clinical benefit rate as well as improving progression-free
survival and overall survival. Most interestingly, the patients in
this study were not enrolled subject to BRCA1/BRCA2 testing
but based on a triple-negative status. These findings add
support to the hypothesis that many basal tumours harbour
defects in the BRCA1 pathway of homologous repair, and
suggest an extended potential for PARP inhibitors.
In conclusion, use of PARP inhibitors is at an early stage;
however, the results obtained are encouraging with respect to
monotherapy as well as an adjuvant in concert with chemo-
therapy. The findings that such drugs may work in triple-
negative tumours on a wider scale suggest a therapeutic
potential beyond use in tumours with defined BRCA1/BRCA2
mutations, although further research in this area is warranted.
Normal breast-like class
The incidence of these tumours varies across different
studies [10], and we lack a clear understanding of their
biology. Notably, tumours of this class seem to carry a poor
prognosis not much different from tumours belonging to the
luminal B class as well as the basal-like cell class [9],
indicating their normal-like gene profile not to be a good
prognostic sign. Based on the results obtained with PARP
inhibition among triple-negative tumours [40], one may
speculate whether some of these tumours may actually
harbour defects in homologous DNA repair – a subject to be
explored in future studies.
Conclusion
Starting out as a nonselective therapy a century ago [41],
following the identification of the ER as a predictive marker,
endocrine therapy in breast cancer has been the ultimate
targeted, or tailored, cancer therapy for three decades. Over
the past decade, tailored therapy with use of anti-HER2
strategies has revolutionized treatment for approximately one-
fifth of breast cancer patients. With the introduction of the
PARP inhibitors, we are now in the process of tailoring
treatment for patients carrying BRCA1 and BRCA2 defect
tumours – and probably also for many additional patients
carrying triple-negative tumours. Although much more
research in this area is warranted, the results achieved up to
now suggest tailored therapy for most, if not all, breast
cancer patients in need of systemic treatment may become a
realistic approach in the near future.
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